Every material Form 8-K REVELATION BIOSCIENCES, INC. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Revelation Biosciences reported results for the three and nine months ended September 30, 2026, with no revenue line in the filing. The net loss grew from a year earlier, and cash fell from $10.7 million at December 31, 2025 to $9.1 million, which the company says will fund operations into the second quarter of 2027.
Net loss for the three months ended September 30, 2026 was $3.3 million, compared with $1.9 million a year earlier.
Net loss for the nine months ended September 30, 2026 was $9.6 million, compared with $6.4 million a year earlier.
Cash and cash equivalents were $9.1 million at September 30, 2026, versus $10.7 million at December 31, 2025; the company expects this to fund operations into the second quarter of 2027.
Net cash used for operating activities was $2.6 million for the third quarter of 2026, compared with $1.6 million in the same period of 2025.
Revelation Biosciences reported results for the three and six months ended June 30, 2026. The net loss for the quarter rose to $3.3 million from $2.4 million a year earlier, and cash and cash equivalents stood at $11.5 million, which the company says is sufficient to fund operations through the first quarter of 2027.
Q2 2026 net loss was $3.3 million, or $0.87 per share, versus $2.4 million, or $28.04 per share, in Q2 2025.
Six-month net loss was $6.3 million, versus $4.5 million for the same period in 2025.
Cash and cash equivalents were $11.5 million at June 30, 2026, up from $10.7 million at December 31, 2025, mainly due to net proceeds from the January 2026 warrant inducement.
Revelation said it is working to start enrollment in its Phase 2/3 acute kidney injury study by year-end.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every REVELATION BIOSCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →